

Zanolimumab

Cat. No.:	HY-P99266
CAS No.:	652153-01-0
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma ^[1] .
In Vitro	Zanolimumab (10 and 100 ng/mL) shows strong killing of the CD4 ⁺ T cells with a better effect to CD45RO ⁺ subset than the CD45RA ⁺ subset ^[1] . Zanolimumab (1-10000 ng/mL) Fc and dose-dependently down-regulates the level of CD4 from purified primary CD4 ⁺ T cells and SUP-T1 T cells ^[1] . Zanolimumab (1-10000 ng/mL) potently inhibits of TCR-stimulated T-cell proliferation both in tetanus toxin induced and anti-CD3 induced T-cell proliferation ^[1] . Zanolimumab (0-30 min) inhibits TCR signal transduction ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Rider DA, et al. A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Res. 2007 Oct 15;67(20):9945-53.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA